This enrolling by invitation study focuses on bipolarity and currently lists sites or participation links in Argentina, Brazil, Colombia, Mexico, United States.
This study exists to understand how the medication OLZ holds up over time after the earliest research stage. For people living with Bipolarity, that matters because care needs to work in daily life, not just in theory. The findings could guide better understanding and future care, and taking part helps build that evidence for others.
The official record suggests in-person participation through a research setting, with sites including Alkermes Investigational Site in Dothan, Alkermes Investigational Site in Little Rock, and Alkermes Investigational Site in Stanford. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually having a stable enough treatment background for the study and meeting the main study requirements, while common reasons not to take part include safety concerns that need urgent care first and active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordTaking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Argentina.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com